Viltolarsen, sold under the brand name Viltepso, is a medication used for the treatment of Duchenne muscular dystrophy (DMD).

[2][1] The most common side effects include upper respiratory tract infection, injection site reaction, cough, and pyrexia (fever).

[2] DMD occurs in approximately one out of every 3,600 male infants worldwide; in rare cases, it can affect females.

[2] The most common side effects include upper respiratory tract infection, injection site reaction, cough, and pyrexia (fever).

[2] In making this decision, the FDA considered the potential risks associated with the drug, the life-threatening and debilitating nature of the disease, and the lack of available therapies.